You are here

  • Home
  • Archive
  • Volume 30, Issue 8
  • A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

Article metrics

Article menu

Download PDFPDF

Clinical trial
A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

 

Online download statistics by month:

Online download statistics by month: June 2020 to April 2024

AbstractFullPdf
Jun 202013112344
Jul 202019819054
Aug 202036235461
Sep 202018418227
Oct 202012212213
Nov 2020868522
Dec 2020635818
Jan 2021807624
Feb 2021797316
Mar 202113313128
Apr 2021848215
May 2021888320
Jun 2021585613
Jul 202152519
Aug 202147448
Sep 2021484621
Oct 2021606029
Nov 2021484619
Dec 2021494815
Jan 2022454824
Feb 2022363813
Mar 2022545318
Apr 2022474725
May 2022787427
Jun 2022727327
Jul 2022524715
Aug 2022716729
Sep 2022675957
Oct 2022696420
Nov 2022514921
Dec 202234339
Jan 2023181915
Feb 2023878219
Mar 2023393713
Apr 2023262611
May 202332307
Jun 2023363511
Jul 2023333115
Aug 2023232211
Sep 202331228
Oct 202319197
Nov 2023413919
Dec 2023403913
Jan 2024383522
Feb 2024514122
Mar 2024413965
Apr 2024181925
Total322130971024